Notably, the biopsy (pre-treatment) and tumor samples (after treatment) obtained from all patients diagnosed with stage II were estrogen receptor ESR1-positive regardless of I2 supplementation (Figure 4D). This evidence concerns the gene ESR1 and neoplasm.